Behet Syndrome¶
Chapter 376 | Part 11: Immune-Mediated, Inflammatory, and Rheumatologic Disorders · Part 11 – Rheumatology & Immunology · Chapter 376
Key Clinical Points¶
- Behçet syndrome is a systemic vasculitis characterized by mucocutaneous involvement.
- Oral ulcers are nearly universal and often the first clinical manifestation.
- Genital ulcers are highly specific for Behçet syndrome and tend to scar.
- Diagnosis is primarily clinical, supported by International Study Group (ISG) criteria.
- Pathergy test identifies a non-specific skin hyperreactivity to trauma (papule/pustule in 24–48 h).
- HLA B*51 is common (50–60%) but not diagnostic due to high prevalence in the general population (~20%).
- Males typically experience more severe disease and poorer outcomes.
- Regional variations exist, particularly regarding gastrointestinal involvement (higher in Japan/USA than Turkey).
- Unlike other autoimmune diseases, it lacks associated autoantibodies or Raynaud's phenomenon.
- Distinguished from autoinflammatory conditions by its tendency to abate over time and lack of specific mutations.
1. DEFINITION & OVERVIEW¶
• Definition: A systemic vasculitis. • Clinical Presentation: ◦ Manifestations include oral and genital ulcers, skin lesions, uveitis, arthritis, major arterial/venous disease, and gastrointestinal/neurologic involvement. ◦ Symptoms may present in various combinations and sequences over time. • Demographics: ◦ Typically rare before the late teens and after age 50. ◦ Males and females are equally affected; however, males frequently have more severe disease and poorer outcomes. • Clinical Clusters: ◦ Evidence suggests different clusters of presentation (e.g., acne lesions more commonly associated with arthritis). ◦ Associated with enthesitis. ◦ Different clusters may suggest distinct underlying pathogenetic mechanisms.
2. EPIDEMIOLOGY¶
• Prevalence: ◦ Most prevalent in Turkey (1 in 250 adults). ◦ Common in Middle East, Mediterranean, and Far East regions. • Gendered Outcomes: ◦ Males frequently experience more severe disease and poorer outcomes. • Regional Variations: ◦ Gastrointestinal involvement: → Rare in Turkey. → More common in Japan. → Seen in ~30% of patients in the United States.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
3.1 Genetic Factors¶
• HLA B*51: ◦ Present in 50–60% of patients (depending on region). ◦ Not used as a diagnostic test because it is found in ~20% of the normal population.
3.2 Immune Mechanisms¶
• Pathogenesis: ◦ Unknown etiology; involves both innate and adaptive immune systems. ◦ Evidence of neutrophil hyperreactivity (status as primary or secondary to cytokine-directed activation is unclear). • Distinction from Other Conditions: ◦ Not typically associated with autoantibodies, Raynaud's phenomenon, Sjögren's syndrome, thrombocytopenia, hemolytic anemia, sun hypersensitivity, or serosal involvement. ◦ Distinguished from autoinflammatory conditions by: → Tendency to abate with time. → Absence of mutations associated with familial Mediterranean fever (Chap. 381).
4. CLINICAL FEATURES¶
4.1 Oral Ulcers¶
• Frequency: Seen in virtually all patients; often the first manifestation. • Characteristics: ◦ Usually multiple. ◦ Last ~10 days; recur unless treated. ◦ Only major ulcers tend to scar. • Clinical Correlation: ◦ Decreased oral health is associated with increased disease severity.
4.2 Genital Ulcers¶
• Specificity: Most specific lesions of the syndrome. • Location: Most commonly on scrotum or labia. • Characteristics: ◦ Larger and deeper than oral ulcers. ◦ Take longer to heal. ◦ Tend to form scars.
4.3 Skin Lesions¶
• Acne-like/Papulopustular: ◦ Indistinguishable from acne vulgaris in appearance and pathology. ◦ Occur at standard acne sites and unusual sites (e.g., lower extremities). • Nodular Lesions: ◦ Erythema nodosum (due to panniculitis). ◦ Superficial vein thromboses. • Clinical Warning: ◦ Superficial thrombophlebitis in men is associated with deep-vein thrombosis. → Should trigger workup for other vascular involvement, including pulmonary artery aneurysms.
4.4 Vascular Involvement¶
• Thrombophlebitis: Often occurs in men; linked to deep-vein thrombosis. • Systemic Risk: → Requires investigation of pulmonary artery aneurysms.
5. DIFFERENTIAL DIAGNOSIS¶
• Diagnostic Basis: ◦ Diagnosis is clinical; no specific laboratory, imaging, or histologic features are definitive for diagnosis. ◦ Tests are primarily used to rule out mimicking conditions. • Clinical Progression: ◦ Some patients may take months to years to develop the full array of symptoms required for a definitive diagnosis. ◦ A tentative diagnosis can often be made well before full presentation.
6. INVESTIGATIONS & DIAGNOSIS¶
6.1 International Study Group (ISG) Criteria¶
• Diagnostic Utility: ◦ Most commonly used and best performing criteria. ◦ Sensitivity: ~95%. ◦ Specificity: ~96%. • Criteria Requirements: ◦ Diagnosis requires recurrent oral ulcers plus 2 of the following 4 clinical manifestations: 1. Oral ulcers: ≈98% frequency; must occur at least 3 times in a 12-month period. 2. Recurrent genital ulcers: ≈80% frequency; usually scarring. 3. Skin lesions: ≈80% frequency; includes erythema nodosum, pseudofolliculitis, papulopustular or acneiform nodules (postadolescent, not receiving corticosteroids). 4. Eye lesions: \50\% frequency; anterior or posterior uveitis, cells in vitreous or retinal vasculitis. 5. Pathergy: \50\% frequency; evaluated 24–48 h after dermal insertion of a 20-gauge needle.
6.2 Pathergy Test¶
• Definition: Non-specific hyperreactivity of the skin to trauma. • Procedure: → Dermal insertion of a 20-gauge needle. → Evaluation at 24–48 h. • Positive Result: Formation of a papule or pustule.
7. MANAGEMENT & TREATMENT¶
- Clinical Diagnosis: → Based on clinical features and ruling out other potential causes.
- Supportive Care: → Dental and periodontal therapies (beneficial for oral health; improved oral health correlates with lower disease severity).
- Monitoring & Progression: → Long-term observation may be required as symptoms can develop over months or years; tentative diagnosis may be made early.
8. PROGNOSIS & COMPLICATIONS¶
• Gendered Prognosis: → Males frequently have more severe disease and poorer outcomes. • Regional Complications: → Gastrointestinal involvement (more common in Japan/USA than Turkey).
9. SPECIAL CONSIDERATIONS¶
• Regional Differences: ◦ Turkey: Gastrointestinal involvement is rare. ◦ Japan: Gastrointestinal involvement is more common. ◦ United States: Gastrointestinal involvement seen in ~30% of patients.
10. KEY PEARLS & CLINICAL TRAPS¶
Diagnostic Pearls¶
• Oral Ulcers: Nearly universal; often the first sign. • Genital Ulcers: Most specific clinical finding. • Pathergy Test: Non-specific skin hyperreactivity to trauma. • HLA B*51: Not a diagnostic test (high prevalence in normal population).
Pathophysiology Pearls¶
• Autoimmunity Profile: → NOT associated with autoantibodies, Raynaud's, Sjögren's, thrombocytopenia, hemolytic anemia, or sun hypersensitivity. • Distinction from Autoinflammatory: → Behçet tends to abate over time. → Absence of mutations associated with familial Mediterranean fever.
Reference Tables¶
TABLE 376-1 International Study Group Criteria for the Diagnosis of Behçet Syndrome CRITERIA Oral ulcers Plus 2 out of…¶
Harrison's 22e, p.2908
| CRITERIA | FREQUENCY | COMMENTS |
|---|---|---|
| Oral ulcers | ~98% | At least 3 times in a 12-month period |
| Recurrent genital ulcers | ~80% | Usually scarring |
| ~80% | ||
| Eye lesions | ~50% | Anterior or posterior uveitis, cells in vitreous or retinal vasculitis |
| ~50% |